Levi Garraway, Roche CMO
Roche nabs a priority review for Evrysdi, hoping to become the first oral treatment for infants with SMA
Roche has been duking it out with Biogen and Novartis ever since bursting into the spinal muscular atrophy space about a year and a half …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
